BioPharma Credit (LSE:BPCR) PE Ratio: 8.42 (As of Jul. 02, 2026) — 24% Below Median


LSE:BPCR BioPharma Credit PLC LSE:BPCR
49 GF Score
Price $0.96
GF Value $0.97
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit PE Ratio?

BioPharma Credit LSE:BPCR +0.63% 49 PE Ratio is 8.42 as of Jul. 02, 2026, which is 24% below its 10-year median of 11.12. GuruFocus rates LSE:BPCR with a GF Score™ of 49/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 2 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-02), BioPharma Credit's share price is $0.96. BioPharma Credit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.11. Therefore, BioPharma Credit's PE Ratio for today is 8.42.

Good Sign:

BioPharma Credit PLC stock PE Ratio (=8.44) is close to 2-year low of 7.95.

During the past 9 years, BioPharma Credit's highest PE Ratio was 16.69. The lowest was 6.09. And the median was 11.12.

BioPharma Credit's EPS (Diluted) for the six months ended in Dec. 2025 was $0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.11.

As of today (2026-07-02), BioPharma Credit's share price is $0.96. BioPharma Credit's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.11. Therefore, BioPharma Credit's PE Ratio without NRI ratio for today is 8.42.

During the past 9 years, BioPharma Credit's highest PE Ratio without NRI was 16.69. The lowest was 6.09. And the median was 11.12.

BioPharma Credit's EPS without NRI for the six months ended in Dec. 2025 was $0.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.11.

During the past 12 months, BioPharma Credit's average EPS without NRI Growth Rate was 14.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was -5.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was 11.40% per year.

During the past 9 years, BioPharma Credit's highest 3-Year average EPS without NRI Growth Rate was 17.30% per year. The lowest was -5.20% per year. And the median was 8.50% per year.

BioPharma Credit's EPS (Basic) for the six months ended in Dec. 2025 was $0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.11.

Back to Basics: PE Ratio


BioPharma Credit  (LSE:BPCR) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


BioPharma Credit PE Ratio Related Terms


BioPharma Credit PE Ratio Historical Data

* Premium members only.

The historical data trend for BioPharma Credit's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioPharma Credit PE Ratio Chart

BioPharma Credit Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only 15.61 7.09 10.12 8.84 8.04

BioPharma Credit Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.12 At Loss 8.84 At Loss 8.04

LSE:BPCR vs BLK, BX, KKR: PE Ratio Comparison

For the Asset Management subindustry, BioPharma Credit's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPharma Credit PE Ratio vs Asset Management Industry

For the Asset Management industry and Financial Services sector, BioPharma Credit's PE Ratio distribution charts can be found below:

* The bar in red indicates where BioPharma Credit's PE Ratio falls into.


LSE:BPCR
49GF Score
BioPharma Credit PLC LSE:BPCR
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioPharma Credit PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

BioPharma Credit's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.96/0.114
=8.42

BioPharma Credit's Share Price of today is $0.96.
For company reported semi-annually, BioPharma Credit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.11.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 8.42 mean?
BioPharma Credit (LSE:BPCR) has a PE Ratio of 8.42 as of Jul. 02, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on BioPharma Credit and its competitors. This is 24% below median its historical median of 11.12. Over the past decade, BioPharma Credit's PE Ratio has ranged from 6.09 to 16.69.
Is BioPharma Credit's PE Ratio too high?
BioPharma Credit's current PE Ratio of 8.42 is 24% below median its 10-year median of 11.12. Over the past 10 years, this metric has ranged from a low of 6.09 to a high of 16.69. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's PE Ratio compare to BLK and BX?
BioPharma Credit's PE Ratio of 8.42 can be compared against companies in the Asset Management industry. Historically, BioPharma Credit's own PE Ratio has ranged from 6.09 to 16.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for an Asset Management company?
A good PE Ratio depends on the Asset Management industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on BioPharma Credit and its competitors. BioPharma Credit's current PE Ratio is 8.42, which is 24% below median its own 10-year median of 11.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current PE Ratio is 8.42, which is 24% below median its 10-year median of 11.12. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current PE Ratio is 8.42 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued. The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • PE Ratio: 8.42 (24% below median its 10-year median of 11.12)
  • GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score

Get the complete analysis for LSE:BPCR

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.97
GF Value